Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.63
+1.78 (1.75%)
At close: Aug 14, 2026, 4:00 PM EDT
103.58
-0.05 (-0.05%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Spyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-178.92-155.2-208.02-338.79-83.82-65.8
Depreciation & Amortization
---0.961.962
Loss (Gain) From Sale of Assets
-70-10--15.53--
Asset Writedown & Restructuring Costs
---132.77--
Loss (Gain) From Sale of Investments
-8.59-8.09-11.4-2.32-0.330.55
Stock-Based Compensation
45.737.6144.8325.687.118.04
Other Operating Activities
7.96-27.6421.71102.530.43-0.34
Change in Accounts Receivable
---0.380.44-0.82
Change in Accounts Payable
2.037.65-16.21-2.18-2.641.07
Change in Unearned Revenue
---0.58-0.883.58
Change in Other Net Operating Assets
-7.12-13.5811.68-3.97-2.42-1.99
Operating Cash Flow
-208.94-169.25-157.41-99.91-80.14-53.72
Operating Cash Flow Growth
------
Capital Expenditures
-----0.04-0.57
Sale of Property, Plant & Equipment
---0.48--
Cash Acquisitions
---3.04--
Sale (Purchase) of Intangibles
707-15--
Investment in Securities
-533.74-150.48-353.29-126.957.05-22.05
Investing Cash Flow
-463.74-143.48-353.29-108.3957.01-22.62
Long-Term Debt Repaid
-----0.42-0.51
Net Debt Issued (Repaid)
-----0.42-0.51
Issuance of Common Stock
781.73314.44243.8984.9643.11.9
Other Financing Activities
-28.71-5.41-1.84-5.8--
Financing Cash Flow
753.03309.03410.91361.0842.681.39
Foreign Exchange Rate Adjustments
---00.03-0.11-0.02
Net Cash Flow
80.35-3.7-99.79152.819.44-74.96
Free Cash Flow
-208.94-169.25-157.41-99.91-80.18-54.29
Free Cash Flow Growth
------
Free Cash Flow Margin
----11276.52%-3442.76%-289.71%
Free Cash Flow Per Share
-2.80-2.64-3.35-14.49-23.78-20.64
Levered Free Cash Flow
-89.05-103.85-66.57-9.61-50.01-30.62
Unlevered Free Cash Flow
-89.05-103.85-66.57-9.61-50.01-30.62
Change in Working Capital
-5.09-5.93-4.53-5.21-5.51.83
SEC Filings: 10-K · 10-Q